222 related articles for article (PubMed ID: 22524513)
1. JAK2V617F allele burden is associated with transformation to myelofibrosis.
Koren-Michowitz M; Landman J; Cohen Y; Rahimi-Levene N; Salomon O; Michael M; Amariglio N; Nagler A
Leuk Lymphoma; 2012 Nov; 53(11):2210-3. PubMed ID: 22524513
[TBL] [Abstract][Full Text] [Related]
2. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.
Passamonti F; Rumi E; Pietra D; Elena C; Boveri E; Arcaini L; Roncoroni E; Astori C; Merli M; Boggi S; Pascutto C; Lazzarino M; Cazzola M
Leukemia; 2010 Sep; 24(9):1574-9. PubMed ID: 20631743
[TBL] [Abstract][Full Text] [Related]
4. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy.
Silver RT; Vandris K; Wang YL; Adriano F; Jones AV; Christos PJ; Cross NC
Leuk Res; 2011 Feb; 35(2):177-82. PubMed ID: 20650526
[TBL] [Abstract][Full Text] [Related]
5. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
6. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
Besses C; Alvarez-Larrán A; Martínez-Avilés L; Mojal S; Longarón R; Salar A; Florensa L; Serrano S; Bellosillo B
Br J Haematol; 2011 Feb; 152(4):413-9. PubMed ID: 21219298
[TBL] [Abstract][Full Text] [Related]
7. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
8. Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Dam MJB; Pedersen RK; Knudsen TA; Andersen M; Skov V; Kjaer L; Hasselbalch HC; Ottesen JT
Eur J Haematol; 2021 Dec; 107(6):624-633. PubMed ID: 34411333
[TBL] [Abstract][Full Text] [Related]
9. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications.
Malak S; Labopin M; Saint-Martin C; Bellanne-Chantelot C; Najman A;
Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):170-6. PubMed ID: 22818858
[TBL] [Abstract][Full Text] [Related]
10. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
Shirane S; Araki M; Morishita S; Edahiro Y; Sunami Y; Hironaka Y; Noguchi M; Koike M; Sato E; Ohsaka A; Komatsu N
Int J Hematol; 2015 Feb; 101(2):148-53. PubMed ID: 25522845
[TBL] [Abstract][Full Text] [Related]
11. JAK2V617F allele burden in patients with myeloproliferative neoplasms.
Alshemmari SH; Rajaan R; Ameen R; Al-Drees MA; Almosailleakh MR
Ann Hematol; 2014 May; 93(5):791-6. PubMed ID: 24362471
[TBL] [Abstract][Full Text] [Related]
12. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea.
Sirhan S; Lasho TL; Hanson CA; Mesa RA; Pardanani A; Tefferi A
Am J Hematol; 2008 May; 83(5):363-5. PubMed ID: 18266209
[TBL] [Abstract][Full Text] [Related]
13. Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy.
Ruella M; Salmoiraghi S; Risso A; Carobbio A; Buttiglieri S; Spatola T; Sivera P; Ricca I; Barbui T; Tarella C; Rambaldi A
Exp Hematol; 2013 Jul; 41(7):627-34. PubMed ID: 23542632
[TBL] [Abstract][Full Text] [Related]
14. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
15. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
16. Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.
Moliterno AR; Williams DM; Rogers O; Isaacs MA; Spivak JL
Exp Hematol; 2008 Nov; 36(11):1480-6. PubMed ID: 18723264
[TBL] [Abstract][Full Text] [Related]
17. [Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].
Bai J; Xue YP; Zhang L; Li CH; Fan DM; Li B; Xu SC; Li DP; Sun XJ; Jiang B; Yang RC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):444-9. PubMed ID: 21518505
[TBL] [Abstract][Full Text] [Related]
18. Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques.
Veneri D; Capuzzo E; de Matteis G; Franchini M; Baritono E; Benati M; Solero GP; Ambrosetti A; Quaresmini G; Pizzolo G
Blood Transfus; 2009 Jul; 7(3):204-9. PubMed ID: 19657484
[TBL] [Abstract][Full Text] [Related]
19. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.
Helbig G; Wieczorkiewicz A; Woźniczka K; Wiśniewska-Piąty K; Rusek A; Kyrcz-Krzemień S
Med Oncol; 2012 Dec; 29(4):2379-84. PubMed ID: 22383244
[TBL] [Abstract][Full Text] [Related]
20. JAK2 V617F allele burden in polycythemia vera: burden of proof.
Moliterno AR; Kaizer H; Reeves BN
Blood; 2023 Apr; 141(16):1934-1942. PubMed ID: 36745865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
